RASSF5 and nasopharyngeal carcinoma: RASSF5 was demonstrated as a target of miR-532-5p; BMSC-Exos may inhibit apoptosis by targeting RASSF5 to deliver miR-532-5p to inhibit NPC apoptosis (Zhu et al., 2020a).